Buffalo, IL, United States of America

Jayanthy Jayanth

This inventor holds 21 USPTO granted patents and 15 published patent applications, plus 7 CIPO patents. Top assignees: Abbvie Inc., Neurocrine Biosciences, Inc.. Active years: 2018-2024.

USPTO Granted Patents = 21 

% Patents Active = 100.0

 

Average Co-Inventor Count = 6.8

ph-index = 11

Forward Citations = 376(Granted Patents)


Location History:

  • Buffalo, IL (US) (2018 - 2020)
  • Buffalo, NY (US) (2021)
  • Buffalo Grove, IL (US) (2018 - 2024)

Company Filing History:


Years Active: 2018-2024

Loading Chart...
Loading Chart...
21 patents (USPTO):Explore Patents

Title: Inventor Jayanthy Jayanth - Revolutionizing Technology

Introduction: Jayanthy Jayanth, a visionary inventor hailing from Buffalo, IL (US), is a prominent figure in the world of technology and innovation.

Latest Patents: Jayanthy Jayanth holds several groundbreaking patents in the fields of artificial intelligence, renewable energy, and biotechnology, showcasing his diverse range of expertise and forward-thinking approach.

Career Highlights: With a career spanning over two decades, Jayanthy Jayanth has worked with leading tech companies and research institutions, contributing significantly to the development of cutting-edge technologies that have shaped industries worldwide.

Collaborations: Throughout his career, Jayanthy Jayanth has collaborated with top scientists, engineers, and researchers, fostering a culture of innovation and excellence in all his projects. His collaborative efforts have led to the creation of revolutionary products and solutions.

Conclusion: Jayanthy Jayanth's passion for innovation, coupled with his relentless drive to push the boundaries of technology, has solidified his position as a trailblazer in the world of inventions. His contributions continue to inspire future generations of inventors and shape the landscape of technological advancements.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…